BioCentury | Aug 5, 2019
Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

...New Enterprise Associates. Sagimet expects top-line data in mid-2020 from a Phase II trial of TVB-2640...
BioCentury | Feb 15, 2019
Company News

3-V raises $18M, partners NASH program with Ascletis

...13 and granted lead investor Ascletis Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640...
...Phase I testing to treat NASH, TVB-2640 reduced mean hepatic de novo lipogenesis from baseline. TVB-2640...
...3-V Biosciences Inc., Menlo Park, Calif. Ascletis Pharma Inc. (HKSE:1672), Hangzhou, China Business: Hepatic Hongjiang Li FAS inhibitor (TVB-2640) 3-V...
BioCentury | Feb 13, 2019
Financial News

3-V raises $18M, partners NASH program with Ascletis

...round and granted lead investor Ascletis Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640...
...TVB-2640 is the first FASN inhibitor to enter clinical development, according to BioCentury's BCIQ database. Hongjiang Li FAS inhibitor...
...is the first FASN inhibitor to enter clinical development, according to BioCentury's BCIQ database. Hongjiang Li FAS inhibitor (TVB-2640) 3-V...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...pinometostat in Phase I testing to treat leukemia. 3-V Biosciences Inc. has the FASN inhibitor TVB-2640...
BioCentury | Oct 27, 2017
Clinical News

3-V reports Phase I data for NASH candidate

...that a once-daily 50 mg dose of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) candidate TVB-2640...
...Menlo Park, Calif. Product: TVB-2640 Business: Endocrine/Metabolic Molecular target: Fatty acid synthase (FASN; FAS) Description: FAS inhibitor...
...of the abdomen and change in skin sebum production Status: Phase I data Milestone: NA Allison Johnson TVB-2640 3-V...
BioCentury | Aug 15, 2016
Finance

Serving returns

...therapy targeting cancer/testis antigen 1B (NY-ESO-1; CTAG1B) to treat cancer Ph I/II 3-V Biosciences Inc. TVB-2640...
BioCentury | Jan 1, 2015
Financial News

3-V Biosciences raises $28.5M series D

...also participated. 3-V expects early efficacy data in 2015 from a Phase I trial of TVB-2640...
...acid synthase ( FASN ; FAS) inhibitor to treat advanced solid tumors. The company said TVB-2640...
BioCentury | Sep 4, 2014
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Crystal structure of the b-ketoacyl reductase (KR) domain of fatty acid synthase (FASN; FAS)-small molecule inhibitor complex The crystal structure of the KR domain of...
BioCentury | Jun 12, 2014
Distillery Therapeutics

Indication: Cancer

...as a-lipoic acid could help protect normal cells from the toxic effects of C75, a FAS inhibitor...
BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...NASDAQ:CELG), Flagship Ventures, Third Rock Ventures, others 3-V Biosciences Inc. Target identification and validation platforms; TVB-2640...
Items per page:
1 - 10 of 13